Assessing outcomes after thrombectomy with or without iliac vein stenting for young provoked DVT patients with iliac vein stenosis

Table 1 The demographics and procedure characteristics of involved patients

Variables		Stenting (n = 17)	Nonstenting (n = 58)	p value
Age, y		36.65 ± 4.61	32.52 ± 8.77	0.0695
Sex (male)		82.35% (14)	63.79% (37)	0.2370
Provoking factor *
	Surgery	17.65% (3)	17.24% (10)	0.5369
	Trauma	47.06% (8)	31.03% (18)
	Immobilization	29.41% (5)	29.31% (17)
	Pregnancy/puerperium	5.88% (1)	13.79% (8)
	Hormone therapy	0 (0)	8.65% (5)
Thrombus location**
	Left	94.12% (16)	81.03% (47)	0.1957
	Right	5.88% (1)	18.97% (11)	0.1957
ART time, s		292.35 ± 88.10	304.76 ± 84.07	0.6032
CDT		58.82% (10)	25.86% (15)	0.0183
Postoperative anticoagulants
	Rivaroxaban	64.70% (11)	67.24% (39)	0.8268
	Warfarin	17.65% (3)	12.07% (7)
	Warfarin to Rivaroxaban ***	17.65% (3)	20.69% (12)
Coagulation function during rivaroxaban
	PT, s	13.22 ± 1.81	12.78 ± 1.54	0.3681
	APTT, s	33.43 ± 5.01	31.40 ± 5.84	0.2457
Coagulation function during warfarin
	INR	2.42 ± 0.19	2.36 ± 0.25	0.7551
Follow-up time		15.06 ± 8.91	18.29 ± 9.44	0.2185

The data were expressed as mean ± standard deviation or percentage (number). ART: AngioJet rheolytic thrombectomy; CDT: catheter-directed thrombolysis
* “Trauma” included all patients had trauma and patients underwent surgery or had prolonged immobilization were excluded. Two patients had both immobilization and surgery, one patient had both immobilization and trauma, and the three patients were counted in “Immobilization”
** In the case of bilateral DVT, the leg with the most proximal localization was considered to be the index leg
*** Fifteen patients requested switch from warfarin to rivaroxaban within 4 weeks after discharge. No adverse event was reported during the drug switch

ISSN: 1477-9560